FT News Briefing

Final US presidential debate, FDA approves remdesivir, Intel data hit by pandemic

Donald Trump and his Democratic challenger, Joe Biden, clashed over issues from the pandemic to foreign policy in their final presidential election debate. Then, the FT’s Demetri Sevastopulo will explain why local races in Texas and around the US could dictate the political make-up of the country for years to come. Plus, Gilead has received the first US regulatory approval for a Covid-19 drug, and Intel reported a decline in data centre revenues and said its earnings fell by nearly a quarter from a year ago due to the pandemic. Donald Trump and Joe Biden clash over coronavirus in final debate<a href="https://www.ft.com/content/bef48683-9bde-4ac2-8906-797779593b22" rel="noopener noreferrer" target="_blank">https://www.ft.com/content/bef48683-9bde-4ac2-8906-797779593b22</a> Gilead secures FDA approval for remdesivir <a href="https://www.ft.com/content/07a321de-109b-46aa-99bc-f884e0ed7703" rel="noopener noreferrer" target="_blank">https://www.ft.com/content/07a321de-109b-46aa-99bc-f884e0ed7703</a> Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer" style="color:grey;" target="_blank">acast.com/privacy</a> for more information.

A rundown of the most important global business stories you need to know for the coming day, from the newsroom of the Financial Times. Available every weekday morning. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer" style="color:grey;" target="_blank">acast.com/privacy</a> for more information.